Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...
With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...
REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year ...
DISABLED ENTREPRENEUR UK on MSN
What is cell & gene therapy AI
Cell and gene therapy are revolutionary approaches to treating diseases at the molecular level. They involve the manipulation ...
This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...
AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the United StatesTherapy granted United States Food ...
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
A MeiraGTx Holdings gene therapy for Parkinson’s disease has preliminary data from a small clinical trial showing the one-time treatment showed both safety and efficacy, results that lay the ...
A retired HGV driver was the first person in the world to take part in a clinical trial to extend the lifespan of blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback